Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Achim Rothe, MD, Stephanie Sasse, MD, Helen Goergen, Dennis A. Eichenauer, MD, Andreas Lohri, MD, Ulrich Jäger, Christopher Bangard, Andreas Engert, MD

Blood (2012) 120 (21): 2743.

https://doi.org/10.1182/blood.V120.21.2743.2743

Published: 2012

Journal Articles

Combined SNP Microarray Based Genomic Mapping and Next Generation Transcriptome Sequencing Confirms the Presence of Somatic STAT3 Mutations and Identifies Novel Chromosomal Imbalances and Candidate Genes in T Large Granular Lymphocytic Leukemia (T-LGL)

Patricia Johansson, Ludger Klein-Hitpass, René Scholtysik, Marc Seifert, Ulrich Jäger, Gertraud Tschurtschenthaler, Ulrich Dührsen, Ralf Küppers, Jan Dürig

Blood (2012) 120 (21): 3512.

https://doi.org/10.1182/blood.V120.21.3512.3512

Published: 2012

Journal Articles

Cannabinoid Receptor 1 in Chronic Lymphocytic Leukemia: Strong Prognostic Marker with Limited Therapeutic Use

Patricia Weiss, Edit Anna Porpaczy, MD, Trang Le, Cathrin Skrabs, Michaela Gruber, Clemens Pausz, Ulrich Jäger, Katrina Vanura

Blood (2012) 120 (21): 4565.

https://doi.org/10.1182/blood.V120.21.4565.4565

Published: 2012

Journal Articles

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Stefan KÖhrer, MD, Greg Coffey, PhD, Ekaterina Kim, MS, Nathalie Y Rosin, PhD, Uma Sinha, PhD, Anjali Pandey, PhD, Medhat Shehata, Ulrich Jäger, Susan M. O'Brien, MD, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Deborah Thomas, MD, Hagop M Kantarjian, Jan A. Burger, MD, PhD

Blood (2012) 120 (21): 3532.

https://doi.org/10.1182/blood.V120.21.3532.3532

Published: 2012

Journal Articles

Differential Expression and Functions of NOTCH Family Members and Involvement of NR4A1 in the Regulation of Apoptosis in CLL

Rainer Hubmann, Martin Hilgarth, Susanne Schnabl, Elena Ponath, Dita Demirtas, Marlies Reiter, Ulrich Jäger, Medhat Shehata

Blood (2012) 120 (21): 3919.

https://doi.org/10.1182/blood.V120.21.3919.3919

Published: 2012

Journal Articles

Green Tea Extract EGCG Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells Through the Regulation of PI3K/Akt Cascade and Proteasome Activity

Elena Ponath, Susanne Schnabl, Martin Hilgarth, Dita Demirtas, Marlies Reiter, Eva Fuchs, Rainer Hubmann, Ulrich Jäger, Medhat Shehata

Blood (2012) 120 (21): 3916.

https://doi.org/10.1182/blood.V120.21.3916.3916

Published: 2012

Journal Articles

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Blood (2012) 120 (21): 433.

https://doi.org/10.1182/blood.V120.21.433.433

Published: 2012

Journal Articles

High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

Daniel Heintel, Arnold Bolomsky, Martin Schreder, MD, Sabine Pfeifer, Niklas Zojer, Ulrich Jäger, Heinz Ludwig, MD

Blood (2011) 118 (21): 2879.

https://doi.org/10.1182/blood.V118.21.2879.2879

Published: 2011

Journal Articles

Inhibition of NOTCH Activity by GLIOTOXIN Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells

Rainer Hubmann, Martin Hilgarth, Susanne Schnabl, Elena Ponath, Dita Demirtas, Marlies Reiter, Christoph Zielinski, Ulrich Jäger, Medhat Shehata

Blood (2011) 118 (21): 4609.

https://doi.org/10.1182/blood.V118.21.4609.4609

Published: 2011

Journal Articles

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

Niels Murawski, MD, Evelyn Kuhnt, Sandra Grass, MD, Wolfgang Hiddemann, MD, Eva Cavallin-Stahl, MD, Georg Hess, MD, Mathias Witzens-Harig, Ingrid Vasova, MD, Ulrich Jäger, MD, Michal Osowiecki, MD, Scott North, MD, Ruth Pettengell, FRACP, PhD, Viola Pöschel, Markus Löffler, Michael Pfreundschuh, MD

Blood (2010) 116 (21): 2826.

https://doi.org/10.1182/blood.V116.21.2826.2826

Published: 2010

Journal Articles

Randomised Intergroup Trial of First line Treatment for young Low-Risk Patients (<61 years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL) with a CHOP-like Regimen with or without the Anti-CD20 Antibody Rituximab – 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group

Blood (2010) 116 (21): 111.

https://doi.org/10.1182/blood.V116.21.111.111

Published: 2010

Journal Articles

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Michael Fridrik, MD, Andreas L Petzer, MD, Felix Keil, MD, Wolfgang Willenbacher, MD, Ulrich Jäger, MD, Alois Lang, MD, Johannes Andel, MD, Otto Krieger, MD, Wilhelm Oberaigner, Richard Greil, MD

Blood (2010) 116 (21): 1766.

https://doi.org/10.1182/blood.V116.21.1766.1766

Published: 2010

Journal Articles

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

Thorsten Zenz, MD, Raymonde Busch, Anna Fink, MD, Dirk Winkler, MD, Kirsten Fischer, MD, Andreas Bühler, MD, Patrick Hoth, Gunter R. Fingerle-Rowson, MD, PhD, Michael Kneba, MD, PhD, Sebastian Boettcher, MD, Ulrich Jäger, MD, Myriam Mendila, MD, Michael Wenger, MD, Peter Lichter, PhD, Michael Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD

Blood (2010) 116 (21): 2427.

https://doi.org/10.1182/blood.V116.21.2427.2427

Published: 2010

Journal Articles

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Blood (2009) 114 (22): 1267.

https://doi.org/10.1182/blood.V114.22.1267.1267

Published: 2009

Journal Articles

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Juergen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz H. Truemper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 329.

https://doi.org/10.1182/blood.V112.11.329.329

Published: 2008

Journal Articles

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler, Andreas Bühler, Raymonde Busch, Günther Fingerle-Rowson, Kirsten Fischer, Anna- Maria Fink, Ulrich Jäger, Sebastian Böttcher, Michael Kneba, Michael Wenger, Myriam Mendila, Michael Hallek, Hartmut Döhner

Blood (2008) 112 (11): 781.

https://doi.org/10.1182/blood.V112.11.781.781

Published: 2008

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Stephan Stilgenbauer, Dirk Winkler, Andreas Bühler, Thorsten Zenz, Silja Groner, Raymonde Busch, Manfred Hensel, Ulrich Dührsen, Jürgen Finke, Peter Dreger, Ulrich Jäger, Eva Lengfelder, Lorenz Trümper, Ulrike Söling, Rudolf Schlag, Michael Hallek, Hartmut Döhner

Blood (2007) 110 (11): 3120.

https://doi.org/10.1182/blood.V110.11.3120.3120

Published: 2007

Journal Articles

Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.

Christine Mayr, MD, Cathrine Schulz, M.D., Stephan Stilgenbauer, M.D., Alexander Kröber, M.D., Hartmut Döhner, M.D., Ulrich Jäger, M.D., Birgit Kainz, M.D., Georg Hopfinger, M.D., Rüdiger Hoffmann, M.D., Clemens Wendtner, M.D., Michael Hallek, M.D., Michael R. Speicher, M.D.

Blood (2006) 108 (11): 2084.

https://doi.org/10.1182/blood.V108.11.2084.2084

Published: 2006

Journal Articles

Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes

Dirk Kienle, Axel Benner, Alexander Kröber, Dirk Winkler, Daniel Mertens, Andreas Bühler, Till Seiler, Ulrich Jäger, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer

Blood (2006) 107 (5): 2090–2093.

https://doi.org/10.1182/blood-2005-04-1483

Published: 2006

Includes: Supplemental data

NARROW

Brentuximab Vedotin (SGN-35) in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies without Prior High-Dose Chemotherapy and Stem Cell Transplantation.

Combined SNP Microarray Based Genomic Mapping and Next Generation Transcriptome Sequencing Confirms the Presence of Somatic STAT3 Mutations and Identifies Novel Chromosomal Imbalances and Candidate Genes in T Large Granular Lymphocytic Leukemia (T-LGL)

Cannabinoid Receptor 1 in Chronic Lymphocytic Leukemia: Strong Prognostic Marker with Limited Therapeutic Use

Efficacy of PRT060318, a Novel Highly Specific SYK Inhibitor, in Acute Lymphoblastic Leukemia (ALL)

Differential Expression and Functions of NOTCH Family Members and Involvement of NR4A1 in the Regulation of Apoptosis in CLL

Green Tea Extract EGCG Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells Through the Regulation of PI3K/Akt Cascade and Proteasome Activity

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

Inhibition of NOTCH Activity by GLIOTOXIN Induces Apoptosis in CLL Cells and Overcomes the Supportive Effect of Primary Bone Marrow Stromal Cells

The Role of the Rituximab Partner Chemotherapy Regimen In Young Patients with Good-Prognosis Diffuse Large B-Cell Lymphoma (DLBCL): Results of the 6-Year Follow-up of the Mint Study of the Mabthera International Trial (MInT) Group.

Is Liposome Encapsulated Doxorubicin Able to Reduce the Cardiotoxicity of Doxorubicin In the Treatment of DLBCL? A Randomised Study by the Austrian Working Party of Medical Oncology (AGMT-study NHL-14)

Genetics of Patients with F-Refractory CLL or Early Relapse After FC or FCR: Results From the CLL8 Trial of the GCLLSG

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG.

Subcutaneous Alemtuzumab (Campath) in Fludarabine-Refractory CLL: Final Results of the CLL2H Trial of the GCLLSG and Comprehensive Analysis of Prognostic Markers

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Subcutaneous Alemtuzumab (MabCampath) in Fludarabine-Refractory CLL (CLL2H Trial of the GCLLSG).

Occurrence of Chromosomal Translocations as Independent Prognostic Factor in Chronic Lymphocytic Leukemia.

Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only